| 29 May 2024, Wednesday |

COVID-19 reinfection rare, but more common in older people, study finds

The majority of people who have had the coronavirus are protected from getting it again for at least 6 months, a study published on Wednesday revealed, noting however that older people are more prone to reinfection than younger people.

The study, appearing in the Lancet medical journal, found that only 0.65% of patients tested positive a second time for COVID-19 after previously being infected during Denmark’s first and second waves. That was much lower than the 3.27% who were positive for the virus using highly accurate PCR tests after initially being negative.

But the study found that people over the age of 65 had only 47% protection against reinfection, compared to 80% protection for younger people.

“Our study confirms what a number of others appeared to suggest: reinfection with the coronavirus is rare in younger, healthy people, but the elderly are at greater risk of contracting it again,” said Steen Ethelberg of Denmark’s Statens Serum Institut.

“Since older people are also more likely to experience severe disease symptoms, and sadly die, our findings make clear how important it is to implement policies to protect the elderly during the pandemic.”

The authors of the study found no evidence that protection against reinfection declined over a 6 month follow-up period, adding that more studies were needed to assess protection against reinfection from variants of COVID-19.

The data analysed was collected through Denmark’s national testing strategy, under which 69% of the population, or 4 million people, were tested over the course of 2020.

Imperial College London professors Rosemary Boyton and Danny Altmann commented on the results, saying the results showed lower protection and were “more concerning” than previous studies.

“These data are all confirmation, if it were needed, that for SARS-CoV-2 the hope of protective immunity through natural infections might not be within our reach and a global vaccination program with high efficacy vaccines is the enduring solution,” they said in a linked comment piece also published in the Lancet.

  • Reuters